首页> 外文期刊>The Canadian journal of cardiology >Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective.
【24h】

Risk stratification, management and outcomes of patients with non-ST elevation acute coronary syndrome: a Canadian teaching hospital perspective.

机译:非ST段抬高的急性冠状动脉综合征患者的风险分层,管理和结果:加拿大教学医院的观点。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Current guidelines for non-ST elevation acute coronary syndromes (NSTACS) recommend tailoring the intensity of therapeutic management according to the baseline risk of the patient. Although the clinical characteristics, risk stratification and therapeutic management of contemporary patients with NSTACS have been reported for other geographical regions, this information has not been documented from a Canadian perspective. OBJECTIVES: To describe the baseline clinical characteristics, therapeutic management and clinical outcomes of contemporary patients with NSTACS at a Canadian, tertiary care, teaching hospital, and to retrospectively risk stratify the patients with NSTACS according to the American College of Cardiology (ACC)/American Heart Association (AHA) and Thrombolysis in Myocardial Infarction (TIMI) risk guidelines to characterize management and outcomes according to the various risk classifications. METHODS: Baseline demographics, procedural variables and clinical outcome data were retrospectively collected in 380 patients with a diagnosis of NSTACS from July 1999 to July 2000. Patients were retrospectively categorized into high, intermediate and low risk categories using two classification schemes. RESULTS: According to the ACC/AHA guidelines, 10.3% and 89.7% of patients were intermediate and high risk, respectively. Applying the TIMI risk score, 20.0%, 52.4% and 27.6% of patients were low, intermediate and high risk, respectively. The use of antithrombotic, acetylsalicylic acid and beta-blocker therapy was very high both in hospital and at discharge. Glycoprotein IIb/IIIa inhibitors, angiotensin-converting enzyme inhibitors and lipid lowering agents were all underutilized. The use of pharmacological therapies and cardiovascular interventions did not appear to correlate with the level of risk of the patient, at least within these classification schemes. Adverse clinical events in hospital and length of hospital stay increased as the risk level of the patients increased. CONCLUSIONS: According to the ACC/AHA guidelines, patients with a discharge diagnosis of NSTACS in a nontrial setting are a high risk population, requiring prompt recognition and aggressive management. This study serves as an integral part of clinical practice to continually evaluate the quality of medical care.
机译:背景:非ST段抬高急性冠脉综合征(NSTACS)的现行指南建议根据患者的基线风险调整治疗管理的强度。尽管已有其他地区报道了当代NSTACS患者的临床特征,风险分层和治疗管理,但从加拿大的角度来看,尚无此信息。目的:描述根据美国心脏病学会(ACC)/ American的加拿大三级护理教学医院的当代NSTACS患者的基线临床特征,治疗管理和临床结局,并回顾性对NSTACS患者进行风险分层心脏协会(AHA)和心肌梗塞溶栓(TIMI)风险指南根据各种风险分类来表征管理和结果。方法:回顾性收集1999年7月至2000年7月诊断为NSTACS的380例患者的基线人口统计资料,程序变量和临床结果数据。采用两种分类方案将患者回顾性分为高,中和低风险类别。结果:根据ACC / AHA指南,分别为10.3%和89.7%的患者为中度和高风险。应用TIMI风险评分,分别有20.0%,52.4%和27.6%的患者为低,中和高风险。在医院和出院时,抗血栓,乙酰水杨酸和β-受体阻滞剂的使用率很高。糖蛋白IIb / IIIa抑制剂,血管紧张素转化酶抑制剂和降脂剂均未得到充分利用。至少在这些分类方案中,药物治疗和心血管干预措施的使用似乎与患者的风险水平无关。随着患者风险水平的提高,医院不良临床事件和住院时间会增加。结论:根据ACC / AHA指南,在非试验性环境中诊断出NSTACS出院的患者属于高危人群,需要迅速识别并积极治疗。这项研究是临床实践中不可或缺的一部分,可以不断评估医疗服务的质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号